Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to test whether the combination of the drugs called tacrolimus (Tac), methotrexate (MTX) and new dosing strategy of another drug called (rabbit Anti-thymocyte Globulin \[ATG\]) will help prevent the development and/or improve severity of acute and/or chronic GVHD.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 60 lat
- •Dostępny dawca szpiku - rodzeństwo (pasujące pod względem genetycznym) lub niespokrewniony dawca
- •Kwalifikacja do intensywnego leczenia przygotowawczego
- •Prawidłowa funkcja serca (wyrzutność minimum 45%)
- •Prawidłowa funkcja nerek (przesączanie powyżej 50 mL/minutę)
- •Prawidłowa funkcja płuc (minimum 50% normy)
- •Prawidłowa funkcja wątroby (wskaźniki poniżej określonych granic)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 60 Years
- Last updated (source)
- October 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Alabama at Birmingham
Birmingham, United States
Trial contact
Zaid S Al Kadhimi, MD
Margaret A Thomas, MPH
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.